Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Perennial Allergic Rhinitis Market 2016 Share, Trend, Segmentation and Forecast to 2022

Monday, October 10, 2016 3:54
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

Global Markets Direct’s, ‘Perennial Allergic Rhinitis – Pipeline Review, H2 2016’, provides an overview of the Perennial Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Perennial Allergic Rhinitis and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/649793-perennial-allergic-rhinitis-pipeline-review-h2-2016

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis 
- The report reviews pipeline therapeutics for Perennial Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Perennial Allergic Rhinitis therapeutics and enlists all their major and minor projects 
- The report assesses Perennial Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Perennial Allergic Rhinitis

Request a sample report @ https://www.wiseguyreports.com/sample-request/649793-perennial-allergic-rhinitis-pipeline-review-h2-2016

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/649793-perennial-allergic-rhinitis-pipeline-review-h2-2016

Key points in table of content .

Table of Contents 
Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 
Global Markets Direct Report Coverage 5 
Perennial Allergic Rhinitis Overview 6 
Therapeutics Development 7 
Pipeline Products for Perennial Allergic Rhinitis – Overview 7 
Pipeline Products for Perennial Allergic Rhinitis – Comparative Analysis 8 
Perennial Allergic Rhinitis – Therapeutics under Development by Companies 9 
Perennial Allergic Rhinitis – Therapeutics under Investigation by Universities/Institutes 10 
Perennial Allergic Rhinitis – Pipeline Products Glance 11 
Late Stage Products 11 
Clinical Stage Products 12 
Perennial Allergic Rhinitis – Products under Development by Companies 13 
Perennial Allergic Rhinitis – Products under Investigation by Universities/Institutes 14 
Perennial Allergic Rhinitis – Companies Involved in Therapeutics Development 15 
Faes Farma, S.A. 16 
Glenmark Pharmaceuticals Ltd. 17 
Hisamitsu Pharmaceutical Co., Inc. 18 
Merck & Co., Inc. 19 
Pfizer Inc. 20 
Shionogi & Co., Ltd. 21 
VentiRx Pharmaceuticals, Inc. 22 
Perennial Allergic Rhinitis – Therapeutics Assessment 23 
Assessment by Monotherapy Products 23 
Assessment by Combination Products 24 
Assessment by Target 25 
Assessment by Mechanism of Action 27 
Assessment by Route of Administration 29 
Assessment by Molecule Type 31 
Drug Profiles 33 
(levocabastine hydrochloride + mometasone furoate) – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
Allergen for Asthma and Perennial Allergic Rhinitis – Drug Profile 34 
Product Description 34 
Mechanism Of Action 34 
R&D Progress 34 
asapiprant – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
bilastine – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
desloratadine – Drug Profile 38 
Product Description 38 
Mechanism Of Action 38 
R&D Progress 38 
emedastine difumarate – Drug Profile 40 
Product Description 40 
Mechanism Of Action 40 
R&D Progress 40 
GSP-301 – Drug Profile 41 
Product Description 41 
Mechanism Of Action 41 
R&D Progress 41 
PF-06444752 – Drug Profile 42 
Product Description 42 
Mechanism Of Action 42 
R&D Progress 42 
PF-06444753 – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
VTX-1463 – Drug Profile 46 
Product Description 46 
Mechanism Of Action 46 
R&D Progress 46 
Perennial Allergic Rhinitis – Dormant Projects 47 
Perennial Allergic Rhinitis – Discontinued Products 48 
Perennial Allergic Rhinitis – Product Development Milestones 49 
Featured News & Press Releases 49 
Aug 13, 2015: PENDOPHARM announces Nasacort Allergy 24H Nasal Spray is now available without a prescription in Canadian Province 49 
Appendix 50 
Methodology 50 
Coverage 50 
Secondary Research 50 
Primary Research 50 
Expert Panel Validation 50 
Contact Us 50 
Disclaimer 51

List of Tables 
Number of Products under Development for Perennial Allergic Rhinitis, H2 2016 7 
Number of Products under Development for Perennial Allergic Rhinitis – Comparative Analysis, H2 2016 8 
Number of Products under Development by Companies, H2 2016 9 
Number of Products under Investigation by Universities/Institutes, H2 2016 10 
Comparative Analysis by Late Stage Development, H2 2016 11 
Comparative Analysis by Clinical Stage Development, H2 2016 12 
Products under Development by Companies, H2 2016 13 
Products under Investigation by Universities/Institutes, H2 2016 14 
Perennial Allergic Rhinitis – Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 15 
Perennial Allergic Rhinitis – Pipeline by Faes Farma, S.A., H2 2016 16 
Perennial Allergic Rhinitis – Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 17 
Perennial Allergic Rhinitis – Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 18 
Perennial Allergic Rhinitis – Pipeline by Merck & Co., Inc., H2 2016 19 
Perennial Allergic Rhinitis – Pipeline by Pfizer Inc., H2 2016 20 
Perennial Allergic Rhinitis – Pipeline by Shionogi & Co., Ltd., H2 2016 21 
Perennial Allergic Rhinitis – Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 22 
Assessment by Monotherapy Products, H2 2016 23 
Assessment by Combination Products, H2 2016 24 
Number of Products by Stage and Target, H2 2016 26 
Number of Products by Stage and Mechanism of Action, H2 2016 28 
Number of Products by Stage and Route of Administration, H2 2016 30 
Number of Products by Stage and Molecule Type, H2 2016 32 
Perennial Allergic Rhinitis – Dormant Projects, H2 2016 47 
Perennial Allergic Rhinitis – Discontinued Products, H2 2016 48

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649793

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.